Arthur Wesley Cowman

Mr. Arthur Wesley Cowman

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2026 in Regenerative Therapy
Verified
Journal Article
Open access
ACArthur Wesley Cowman
Arthur Wesley Cowman
JTJordan N. Tang
Jordan N. Tang
JDJeffrey Deng
Jeffrey Deng
AAAmmar Abu-Halawa
Ammar Abu-Halawa
HJHaiyue Jin
Haiyue Jin
HDHongwen Deng
Hongwen Deng
Osteoarthritis is characterized by cartilage degradation and joint distortion. The most prevalent version of osteoarthritis, knee osteoarthritis (KOA), affects millions, acting as a leading cause of disability. With the average life expectancy continuing to grow, the global burden of KOA is expected to increase. KOA involves chronic pain that limits function and adversely impacts patients' quality of life. Long-term management is costly and burdensome, often requiring continuous treatment that only delays disease progression unless patients receive a total knee arthroplasty. Recently, traditional treatment modalities for KOA have been augmented by advancements in machine learning (ML), which enable automated disease grading, predictive modeling for early diagnosis, and personalized treatment strategies, alongside growing interest in stem cell-based therapies. With the goal of developing less invasive treatments that slow or reverse KOA progression, investigation into these novel therapies have increased. Stem cell-based therapies offer the potential to modulate inflammation, reduce pain, and preserve cartilage integrity, addressing key limitations of existing treatments. Mesenchymal stem cells have shown promising preclinical and clinical results, demonstrating improvements in pain, function, and cartilage-related outcomes through immunomodulatory and paracrine mechanisms. This narrative review synthesizes current evidence on conventional and emerging therapies for KOA, with a dual focus on ML-driven clinical applications and stem cell-based regenerative strategies, and discusses their potential roles in improving diagnosis, treatment selection, and patient outcomes. While further research is needed to understand the full potential of stem cells for treating KOA, these promising findings make it a useful topic for current and future clinical applications.

6 December 2025 in European Spine Journal
Verified
Journal Article
Open access
PDF file
RHRyan Hoang
Ryan Hoang
ACArthur Wesley Cowman
Arthur Wesley Cowman
HJHaiyue Jin
Haiyue Jin
PTPhanisri Tummala
Phanisri Tummala
LLLauren Liu
Lauren Liu
ATAlekos A. Theologis
Alekos A. Theologis
Background Thoracic pedicle subtraction osteotomies (T-PSO) are used to correct severe primary and revision thoracic spinal deformities. While lumbar PSOs are well established, literature describing the efficacy and safety of T-PSOs remains limited. This systematic review aims to characterize indications, correction magnitudes, and complications associated with T-PSO. Methods A systematic review was conducted across PubMed, Web of Science, and Scopus in accordance with PRISMA guidelines. Studies were included if they reported outcomes specific to T-PSO in either primary or revision surgeries. Surgical correction characteristics, thoracic region sub-analyses, and adverse events were summarized. Results Data were extracted from 52 studies, including 38 case reports/series and 14 retrospective chart reviews. Among 404 T-PSO patients, 167 patients had the level of procedure reported. Most procedures were single-level osteotomies (n = 161, 96.4%), with the most frequent levels at T11 and T12. The most common indications for T-PSO based on thoracic region were postoperative kyphosis (n = 15, 32.6%) for the upper thoracic spine, thoracic kyphosis (n = 3, 37.5%) alongside thoracic kyphoscoliosis (n = 3, 37.5%) for the middle thoracic spine, and thoracolumbar kyphosis (n = 54, 50.5%) for the lower thoracic spine. Mean magnitude of thoracic kyphosis correction was 25.8° and correction at the T-PSO level was 25.5°. Adverse events occurred in 48.5% of patients, including structural complications (22.5%), instrumentation failures (11.8%), infections (10.8%), and neurologic deficits (9.8%). Three deaths were reported. Complication rates were similar between primary and revision procedures. Conclusion T-PSO achieves meaningful sagittal plane correction in appropriately selected patients with severe and/or rigid primary and revision thoracic spinal deformities. However, high complication rates emphasize the importance of careful patient selection and surgical planning. Standardization of outcome reporting is critical to optimize future clinical guidance.

12 October 2026 in Spine Open
Verified
Journal Article
Open access
MRMelissa Romoff
Melissa Romoff
SYShahabeddin Yazdanpanah
Shahabeddin Yazdanpanah
Ryan BeyerRyan Beyer
Ryan Beyer
ACArthur Wesley Cowman
Arthur Wesley Cowman
ETEmily Tse
Emily Tse
EMEmily S Mills
Emily S Mills
Study Design: Retrospective propensity score-matched cohort study. Objective: To evaluate the association between preoperative gabapentinoid use postoperative pseudoarthrosis, reoperation, and medical complications following adult spinal deformity (ASD) surgery. Summary of Background Data: Gabapentinoids are increasingly prescribed for neuropathic and radicular pain and have demonstrated inhibitory effects on bone metabolism and spinal fusion formation in preclinical models. While prior studies have examined chronic gabapentinoid use in short-segment lumbar fusion, no study has evaluated their impact in ASD surgery, where construct length and baseline pseudoarthrosis are substantially greater. Materials and Methods: Adult patients undergoing ASD correction between 2015 and 2022 were identified using the TriNetX Research Network. Patients with preoperative gabapentinoid prescription within 90 days before surgery were compared with nonusers. Exclusion criteria included trauma, neoplasm, infection, prior fusion, revision surgery, and preoperative opioid use. One-to-one propensity score matching was performed on demographics, comorbidities, and medication use. Primary outcomes included pseudoarthrosis and reoperation at one-year, two-year, and three-year follow-up. Secondary outcomes included 90-day medical complications, including venous thromboembolism, surgical site infection, acute kidney injury, pneumonia, stroke, and myocardial infarction. Results: After propensity score matching, 477 gabapentinoid users were matched to 477 nonusers. Baseline demographics and surgical complexity were well balanced between cohorts. No significant differences were observed in 90-day medical complications or reoperation rates at any time point. However, preoperative gabapentinoid use was associated with significantly increased pseudoarthrosis rates at all follow-up intervals. Pseudoarthrosis occurred in 18.18% versus 9.70% of patients at one year and 23.08% versus 11.74% at three years among gabapentinoid users versus nonusers, respectively (all P <0.0001). Conclusion: Preoperative gabapentinoid use was associated with an approximately two-fold increased risk of pseudoarthrosis following ASD surgery without corresponding increases in perioperative complications or reoperation. These findings suggest gabapentinoid exposure may represent an underrecognized modifiable risk factor for failed fusion in ASD surgery and warrants prospective investigation.

18 July 2026 in Injury
Verified
Journal Article
Open access
MMMengistu G Mengesha
Mengistu G Mengesha
SYShahabeddin Yazdanpanah
Shahabeddin Yazdanpanah
HDHermella Damenu
Hermella Damenu
SBSultan Baz
Sultan Baz
HHHana-Joy E Hanks
Hana-Joy E Hanks
HWHao-Hua Wu
Hao-Hua Wu

27 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RHRyan Hoang
Ryan Hoang
Junho SongJunho Song
Junho Song
ACArthur Wesley Cowman
Arthur Wesley Cowman
THTimothy Hoang
Timothy Hoang
AYAlexander Yu
Alexander Yu
RPRobert L. Parisien
Robert L. Parisien
Background: Anterior cruciate ligament reconstruction (ACLR), one of the most frequently performed orthopedic procedures, has experienced rising demand and escalating costs, driving efforts to reduce expenses through shorter hospital stays and an increased shift toward outpatient settings. This study aims to evaluate how differing definitions of “outpatient” surgery influence the interpretation of outcomes following ACLR. Methods: ACS-NSQIP was queried for patients undergoing primary ACL reconstruction between 2014 and 2023. Patients ≥ 18 years with CPT code 29888 were included. Patients with missing hospital length of stay (LOS) data or a LOS > 2 days (≥99th percentile) were excluded. Two definitions of “outpatient” surgery were evaluated: hospital-defined outpatient (HDO) and same-day discharge (SDD, LOS = 0). Propensity score matching of baseline demographics and comorbidities was used to compare HDO and SDD cohorts to their respective inpatient counterparts. Primary outcomes analyzed included 30-day readmission, reoperation, and postoperative complications. Univariate and multivariate analyses were performed to compare risks of complications for HDO and SDD cohorts compared to their inpatient counterparts. Results: A total of 37,546 patients were included in this study, with 35,334 HDO (94.1%) and 34,801 (92.7%) SDD cases. 1021 (2.9%) of the 35,334 HDO patients had an inpatient hospital stay of at least 1 night. In propensity-matched cohorts, hospital-defined inpatient ACLR was associated with significantly greater risk of 30-day reoperation (odds ratio [OR] 3.167, 95% CI 1.267–7.915, p = 0.009) and superficial surgical site infection (SSI) (OR 5.0, 95% CI 1.712–14.604 p = 0.001), while HDO ACLR was associated with increased risk of deep vein thrombosis (DVT) (OR 0.333, 95% CI 0.121–0.916, p = 0.025). Compared to the propensity-matched SDD cohort, inpatient ACLR was significantly associated with greater rates of 30-day readmission (OR 1.988, 95% CI 1.088–3.630, p < 0.001), reoperation (OR 3.222, 95% CI 1.528–6.794, p = 0.001), and superficial SSI (OR 3.286, 95% CI 1.412–7.644, p = 0.003). Conclusions: This study found differences in readmission and deep vein thrombosis between HDO and SDD cohorts when compared to inpatient ACLR. A standardized definition of outpatient surgery should be created to clearly distinguish same-day discharge from other outpatient categories, considering discharge timing and patient monitoring practices.

9 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HWHaley Willem
Haley Willem
TATyler Aguilar
Tyler Aguilar
ACArthur Wesley Cowman
Arthur Wesley Cowman
KLKristel Adeline Lourdault
Kristel Adeline Lourdault
RERichard Essner
Richard Essner
Imaging techniques used for the care of cutaneous melanoma patients have greatly changed over the past century, from symptom-driven radiography toward a multimodality framework integrated for staging, directing surgery, and systemic therapy, and surveillance. Historically, clinical evaluation and skin exams have been the tenets of melanoma diagnosis and staging. In recent years, noninvasive imaging, such as dermoscopy, total-body photography and reflectance confocal microscopy, has expanded the diagnostic toolset for primary melanoma detection. Concurrently, several imaging techniques have been developed to detect metastases and follow disease progression, including computed tomography (CT), magnetic resonance imaging (MRI), fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT), lymphoscintigraphy, and single-photon emission computed tomography/computed tomography (SPECT/CT). The use of immune checkpoint inhibitors has also altered imaging interpretation by introducing atypical response patterns, including pseudoprogression, requiring immune-adapted assessment frameworks such as Immune Response Evaluation Criteria in Solid Tumors (iRECIST). While there is a strong consensus for high-risk patients, imaging techniques and surveillance schedules for low-risk patients (stage I/II) remain controversial due to limited supporting evidence and conflicting data on costs and patient benefit. The development of new technologies, including image-guided surgery, non-FDG PET tracers, phone apps, artificial intelligence-assisted image analysis, and radiomics, may further change melanoma imaging. The aim of this review is to detail the historical evolution of melanoma imaging, the development of new imaging techniques, and their role and future in clinical practice.